ERBB2 and ovarian carcinoma: Estimates of HER2 overexpression in ovarian cancer varies, with values ranging between 22–66%, with a contribution of genomic amplification in 11% [143], and 6–30%, with an estimate of only 3% for serous ovarian cancer [142].